Immune checkpoint inhibitors (ICIs) play a pivotal role in enhancing antitumor T-cell responses through mechanisms such as blocking CTLA-4, PD-1, or PD-L1. While these interventions can potentiate effective immune responses against tumors, they also have a significant downside: the potential development of immune-related adverse events (irAEs) affecting various organs. Patients may exhibit toxicity simultaneously with therapeutic efficacy, yet this does not imply that tissue damage is an inevitable consequence of successful antitumor activity. Investigators reported that various factors—including shared antigens, lymphocyte clonality, and weakened immune regulation—can create an overlap between effective tumor control and damage to normal tissues during immune activation and response phases.
This interplay is further complicated by organ-specific considerations. Local antigen presentation, cellular interactions, and the integrity of tissue barriers can determine the variance in toxicity across different organs. Current evidence supporting these processes aligns most closely with findings from colitis, though similar insights in other tissues remain less comprehensive. Notably, the presence of tumor-reactive T cells within a specific organ does not automatically equate to preserved antitumor efficacy. Strategies aimed at restricting organ-specific homing, enhancing barrier protection, and targeting inflammatory pathways have shown promise in preclinical models and early clinical observations. However, the effects of these interventions on sustained tumor control are still under investigation, leaving numerous questions unanswered.
The recognition of shared or analogous antigens between tumors and normal tissues is significant. A cohort study involving patients with non-small-cell lung cancer who received anti-PD-1 therapy indicated that 25 out of 73 patients developed autoimmune skin toxicity due to shared antigens stimulating T-cell responses. This is a compelling example of how T-cell clones can mistakenly attack both malignant and healthy tissues. Researchers noted similar findings where high-frequency T-cell clones from patients with fatal myocarditis were present in both tumors and muscle tissues, linking antigen similarity to tissue damage.
However, the causal relationship remains hazy; clonal overlap does not unequivocally pinpoint pathogenicity necessitating further in-depth investigation. The outcome hinges on whether T-cell clones are truly targeting shared antigens or reacting due to sampling biases. Data informed by T-cell receptor (TCR) sequencing hint at the complexities involved in establishing this relationship.
The interplay between B cells and T cells during ICI treatment may serve as a predictive factor for toxicity. Peripheral B-cell populations show alterations such as reduced total B cells and increased plasmablasts in response to combined CTLA-4 and PD-1 blockade. Such changes can precede severe irAEs, suggesting a link worthy of further exploration. Moreover, helper T cells (ICOS-positive) may boost these B-cell responses, enhancing tumor immunity while concurrently presenting risks for adverse immune responses.
Identifying patients at heightened risk for irAEs requires careful monitoring of these cellular dynamics, though direct therapeutic implications remain unclear. Strategies that enhance regulatory T-cell activity or target specific helper signals might limit toxicity but require a clear understanding of how T-cell interactions contribute to adverse events.
Local effects of ICIs manifest distinctly in conditions like colitis. Studies have indicated that tissue-resident memory T cells (TRM) significantly contribute to inflammation in the gut, confirming that local activation and persistence are critical to pathology. Notably, ongoing research has explored therapeutic avenues like the JAK inhibitor tofacitinib, which has shown promise in limited cases, yet wider efficacy and safety remain to be determined across diverse cohorts.
The NLRP3 inflammasome pathway is highlighted in cardiac injury associated with ICIs, revealing potential treatment strategies to mitigate such damage while analyzing concurrent tumor responses. Understanding the intricate mechanisms of tissue injury involves not only recognizing the presence of inflammatory T cells but also deciphering the role of subcellular interactions and local immune environments in mediating these effects.
Current strategies aim to delineate pathways that reduce toxicity without sacrificing therapeutic efficacy. Interventions to minimize gut permeability, mitigate organ-specific inflammation, and reduce systemic side effects present exciting avenues for enhancing patient outcomes. Yet, suitable clinical trials that adequately assess the safety and efficacy of these approaches remain limited.
While the evidence thus far exhibits a promising direction for improving toxicity management in ICI therapy, concrete data delineating preventative success and sustained tumor control requires further rigorous research. Numerous trials must investigate candidates carefully to determine whether these interventions can indeed foster protective effects while ensuring continued effectiveness against malignancies, emphasizing a need for concurrent assessment of toxicity versus efficacy.